Trinity Biotech (TRIB) Finished Goods (2016 - 2025)

Trinity Biotech (TRIB) posted quarterly Finished Goods of $3.6 million for Q4 2025, down 17.18% year-on-year from $4.4 million in Q4 2024, and down 17.18% on a QoQ basis from $4.4 million in Q4 2024.

Trinity Biotech (TRIB) Finished Goods (2016 - 2025) Analysis & Trends

Trinity Biotech (TRIB) has reported Finished Goods for 7 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

  • Quarterly Finished Goods fell 17.18% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (down 17.18% YoY) and the FY2025 annual result came in at $3.6 million, down 17.18% from the prior year.
  • Finished Goods declined to $3.6 million in Q4 2025 per TRIB's latest filing, from $4.4 million in the prior quarter.
  • Over the last five years, Finished Goods for TRIB reached as high as $4.4 million in Q4 2024 and fell as low as $3.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Trinity Biotech 93,750.00 -5.04 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 3.61 Mn
Dec 31, 2024 4.35 Mn
Dec 31, 2020 12.88 Mn
Dec 31, 2019 12.43 Mn
Dec 31, 2018 11.56 Mn
Dec 31, 2017 15.22 Mn
Dec 31, 2016 16.13 Mn